Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM6B | O15054 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011843 | 0.90 | MAOA (0.43) | MAOATSHRDRD2HSD17B10KDM4E | |
| SCHEMBL8024842 | 0.77 | MAOA (0.43) | MAOADRD2DRD4KDM6BKDM4C | |
| SCHEMBL1009757 | 0.76 | MAOA (0.46) | MAOATSHRDRD2HSD17B10KDM4E | |
| SCHEMBL1009030 | 0.75 | MAOA (0.33) | MAOATSHRDRD2HSD17B10KDM4E | |
| SCHEMBL1011572 | 0.75 | DRD2 (0.39) | MAOATSHRDRD2DRD3 | |
| SCHEMBL1009848 | 0.73 | MAOA (0.47) | MAOATSHRDRD2HSD17B10KDM4E | |
| SCHEMBL1009592 | 0.73 | BRD4 (0.48) | MAOA | |
| SCHEMBL1010812 | 0.73 | MAOA (0.46) | MAOATSHRDRD2HSD17B10KDM4E | |
| SCHEMBL1011669 | 0.73 | MAOA (0.46) | MAOATSHRDRD2HSD17B10KDM4E | |
| SCHEMBL1012823 | 0.72 | MAOA (0.46) | MAOATSHRDRD2HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | disclosed |
| EP-2295439-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2011-03-16 | — | — | EP | disclosed |
| EP-2054416-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2011-01-05 | — | — | EP | disclosed |
| EP-2089381-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008068184-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | MAOA 3070/4885TSHR 609/4885DRD2 69/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | MAOA 2896/4885TSHR 925/4885DRD2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.